Contact
searchSearch
HMP Global
Login

News

FDA Approval
FDA Approves Durvalumab Plus BCG for BCG-Naïve Patients With Non-Muscle Invasive Bladder Cancer
05/28/2026
Stephanie Holland
Based on results from the phase 3 POTOMAC study, the FDA has approved durvlaumab plus Bacillus Calmette-Guerin (BCG) for BCG-naïve patients with high-risk non-muscle invasive bladder cancer.
Based on results from the phase 3 POTOMAC study, the FDA has approved durvlaumab plus Bacillus Calmette-Guerin (BCG) for BCG-naïve patients with high-risk non-muscle invasive bladder cancer.
Based on results from the phase...
05/28/2026
Oncology
News
Detalimogene Voraplasmid Shows Promise in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
05/22/2026
Emily Estrada
Interim results from cohort 1 of the phase 2 LEGEND study demonstrated that detalimogene voraplasmid showed encouraging efficacy and safety in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Interim results from cohort 1 of the phase 2 LEGEND study demonstrated that detalimogene voraplasmid showed encouraging efficacy and safety in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Interim results from cohort 1 of...
05/22/2026
Oncology
News
Detalimogene Voraplasmid Shows Promise in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
05/22/2026
Emily Estrada
Interim results from cohort 1 of the phase 2 LEGEND study demonstrated that detalimogene voraplasmid showed encouraging efficacy and safety in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Interim results from cohort 1 of the phase 2 LEGEND study demonstrated that detalimogene voraplasmid showed encouraging efficacy and safety in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Interim results from cohort 1 of...
05/22/2026
Oncology
News
Pembrolizumab Plus BCG Shows Bladder-Preserving Potential in Non-Muscle Invasive Bladder Cancer
05/20/2026
Stephanie Holland
Results from a phase 2 trial demonstrated that pembrolizumab plus bacillus Calmette-Guérin (BCG) demonstrated encouraging bladder-preserving activity in very high-risk non-muscle-invasive bladder cancer.
Results from a phase 2 trial demonstrated that pembrolizumab plus bacillus Calmette-Guérin (BCG) demonstrated encouraging bladder-preserving activity in very high-risk non-muscle-invasive bladder cancer.
Results from a phase 2 trial...
05/20/2026
Oncology
News
Durvalumab Plus BCG Delays High-Risk Recurrence in Non-Muscle-Invasive Bladder Cancer
05/19/2026
Stephanie Holland
Updated results from the POTOMAC trial demonstrate that durvalumab plus Bacillus Calmetter-Guerin (BCG) induction and maintenance reduced recurrence-related outcomes in patients with high-risk non-muscle-invasive bladder cancer.
Updated results from the POTOMAC trial demonstrate that durvalumab plus Bacillus Calmetter-Guerin (BCG) induction and maintenance reduced recurrence-related outcomes in patients with high-risk non-muscle-invasive bladder cancer.
Updated results from the POTOMAC...
05/19/2026
Oncology
FDA Approval
FDA Approves Atezolizumab for Patients with ctDNA-Positive Muscle-Invasive Bladder Cancer
05/15/2026
Emily Estrada
Based on results from the IMvigor011 trial, the FDA has approved adjuvant atezolizumab and atezolizumab plus hyaluronidase for ctDNA-positive patients with muscle-invasive bladder cancer.
Based on results from the IMvigor011 trial, the FDA has approved adjuvant atezolizumab and atezolizumab plus hyaluronidase for ctDNA-positive patients with muscle-invasive bladder cancer.
Based on results from the...
05/15/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology
Pooja Ghatalia, MD
Videos
RETAIN-2 Supports Response-Adapted Bladder Preservation in Muscle-invasive Bladder Cancer
02/27/2026
Pooja Ghatalia, MD
Pooja Ghatalia, MD, discusses results from the phase 2 RETAIN-2 trial and integrated ctDNA analysis from RETAIN-1 and RETAIN-2 evaluating response-adapted bladder preservation in muscle-invasive bladder cancer.
Pooja Ghatalia, MD, discusses results from the phase 2 RETAIN-2 trial and integrated ctDNA analysis from RETAIN-1 and RETAIN-2 evaluating response-adapted bladder preservation in muscle-invasive bladder cancer.
Pooja Ghatalia, MD, discusses...
02/27/2026
Oncology
News
Post-Treatment Plasma ctDNA Accurately Identifies Recurrence in Muscle-Invasive Bladder Cancer
02/09/2026
Stephanie Holland
According to results from a retrospective analysis, plasma ctDNA demonstrated strong potential as a biomarker for early detection of metastatic recurrence in patients with muscle-invasive bladder cancer treated with trimodality therapy.
According to results from a retrospective analysis, plasma ctDNA demonstrated strong potential as a biomarker for early detection of metastatic recurrence in patients with muscle-invasive bladder cancer treated with trimodality therapy.
According to results from a...
02/09/2026
Oncology

Recent News

News
Anti T-Lymphocyte Globulin Remains Standard GVHD Prophylaxis Following Unrelated Donor Transplantation
06/16/2026
Emily Estrada
Results from a phase 3 trial demonstrated that post-transplant cyclophosphamide did not achieve noninferiority to anti–T-lymphocyte globulin for overall survival following unrelated donor alloHCT in patients with high-risk myeloid...
Results from a phase 3 trial demonstrated that post-transplant cyclophosphamide did not achieve noninferiority to anti–T-lymphocyte globulin for overall survival following unrelated donor alloHCT in patients with high-risk myeloid...
Results from a phase 3 trial...
06/16/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Significantly Improves Outcomes in Heavily Pretreated Relapsed or Refractory Multiple Myeloma
06/16/2026
Emily Estrada
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2...
06/16/2026
Oncology
News
In Vivo CAR T-Cell Therapy Shows Encouraging Early Activity in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
06/16/2026
Emily Estrada
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1...
06/16/2026
Oncology
News
Gilteritinib Fails to Improve OS in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
06/16/2026
Emily Estrada
Results from the phase 3 HOVON156/AMLSG28-18/PASHA trial demonstrated that gilteritinib did not significantly improve overall survival compared with midostaurin when combined with intensive chemotherapy in patients with newly diagnosed...
Results from the phase 3 HOVON156/AMLSG28-18/PASHA trial demonstrated that gilteritinib did not significantly improve overall survival compared with midostaurin when combined with intensive chemotherapy in patients with newly diagnosed...
Results from the phase 3...
06/16/2026
Oncology
News
Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Emerges as Potential New Standard in Relapsed or Refractory Chronic Lymphocytic Leukemia
06/16/2026
Stephanie Holland
Results from the phase 3 BRUIN CLL-322 trial demonstrated that pirtobrutinib plus venetoclax and rituximab significantly improved outcomes compared with venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia.
Results from the phase 3 BRUIN CLL-322 trial demonstrated that pirtobrutinib plus venetoclax and rituximab significantly improved outcomes compared with venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia.
Results from the phase 3 BRUIN...
06/16/2026
Oncology
News
Switchable Allogeneic CAR T-Cell Therapy Shows Early Promise in Relapsed or Refractory Acute Myeloid Leukemia
06/16/2026
Emily Estrada
Results from the phase 1a RevSTAR-123 study demonstrated that an investigational switchable allogeneic CD123-directed CAR T-cell therapy showed encouraging clinical activity in heavily pretreated relapsed or refractory acute myeloid leukemia.
Results from the phase 1a RevSTAR-123 study demonstrated that an investigational switchable allogeneic CD123-directed CAR T-cell therapy showed encouraging clinical activity in heavily pretreated relapsed or refractory acute myeloid leukemia.
Results from the phase 1a...
06/16/2026
Oncology
News
CD5 Inhibition Enhances Activity of T-Cell Engagers Across Tumor Types
06/16/2026
Stephanie Holland
Results from a translational study identified CD5 as a key negative regulator of T-cell engager activity and suggest that CD5 inhibition may enhance responses to multiple CD3-engaging therapies.
Results from a translational study identified CD5 as a key negative regulator of T-cell engager activity and suggest that CD5 inhibition may enhance responses to multiple CD3-engaging therapies.
Results from a translational...
06/16/2026
Oncology
News
Talquetamab-Based Regimens Improve Survival in Relapsed or Refractory Multiple Myeloma
06/16/2026
Stephanie Holland
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3...
06/16/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Emerges as Potential New Standard in High-Risk Diffuse Large B-Cell Lymphoma
06/15/2026
Stephanie Holland
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3...
06/15/2026
Oncology
News
Blinatumomab Improves Survival and Reduces Toxicity in Pediatric Patients With High-Risk B-Acute Lymphoblastic Leukemia
06/15/2026
Stephanie Holland
Results from a phase 2 study demonstrated that replacing 2 intensive chemotherapy courses with blinatumomab improved outcomes and reduced treatment-related toxicity in newly diagnosed pediatric patients with high-risk B-cell acute...
Results from a phase 2 study demonstrated that replacing 2 intensive chemotherapy courses with blinatumomab improved outcomes and reduced treatment-related toxicity in newly diagnosed pediatric patients with high-risk B-cell acute...
Results from a phase 2 study...
06/15/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use